GO
Loading...

Johnson & Johnson

More

  • Your First Move For Monday Jan. 7th Friday, 4 Jan 2008 | 7:25 PM ET

    Here's our Fast Money Final Trade. Our gang gives you Monday's best trades, right now!

  • Amgen: Anemia Drugs Take Yet Another Hit Thursday, 3 Jan 2008 | 4:18 PM ET

    The Food and Drug Administration late this morning put out a news release with the heading, "FDA Receives New data on Risks of Anemia Drugs." This is more bad news for an additional population of cancer patients and, of course, Amgen and, to a lesser extent, Johnson and Johnson.

  • Sector Rotation for Dummies Monday, 24 Dec 2007 | 2:16 PM ET

    There are two kinds of companies in the market – cyclical and secular. One of the most important moves in the game is to know when to shift money from one to the other.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Did Genentech Back Down or Backpedal? Friday, 21 Dec 2007 | 12:11 PM ET

    So, it didn't take long after my Genentech blog entry got posted yesterday for me to receive an email and a voicemail from a Genentech spokesperson requesting a "clarification" on my take regarding the latest chapter in the Avastin vs. Lucentis brouhaha. I think I'm being spun.

  • Most of my PR and professional contacts send Christmas cards, but for the past two years the boutique Wall Street firm, Rodman & Renshaw, has sent me heavy metal piggy banks. I assume the company sends them to its clients as well.

  • Your First Move For Thursday Dec. 13th Wednesday, 12 Dec 2007 | 7:08 PM ET

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • Pharma's Market with Mike Huckman Wednesday, 12 Dec 2007 | 4:30 PM ET

    Last year one of our producers had the bright idea of assigning each of CNBC's beat reporters a story about seven predictions for their beat for 2007. So, now this year not only do we have to do the 8 for '08 thing for TV, but also for the blog.

  • The 2008 Beijing Olympics present an unparalleled marketing opportunity for global brands looking to expand their presence in the dynamic Chinese market.

  • Johnson & Johnson's $4 Billion "Oops, Never Mind!" Friday, 30 Nov 2007 | 1:58 PM ET

    Late yesterday one of the midnight-oil-burning "Squawk Box" producers runs over to my desk asking, "Hey, is this J and J thing a big deal?" I said, "What J and J thing?" "Check the wires," he said. Here's what I saw...

  • US Panel Backs Abbott's Drug-Coated Heart Stent Thursday, 29 Nov 2007 | 9:18 PM ET

    Abbott Laboratories moved closer to joining the U.S. market for drug-coated heart stents on Thursday as an advisory panel backed the company's experimental device.

  • J&J to Focus Beyond Traditional Lines of Business Thursday, 15 Nov 2007 | 1:16 PM ET
    Johnson & Johnson

    Health care products maker Johnson & Johnson, faced with lagging sales of some top products, said Thursday it would create three new units to boost prospects.

  • Buy Wyeth? Tuesday, 13 Nov 2007 | 10:39 AM ET

    What's the best reason to own a pharma stock right now? Consistency in the face of recession.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Warnings Strengthened for Amgen, J&J Anemia Drugs Thursday, 8 Nov 2007 | 1:50 PM ET

    The warning labels have been strengthened on anemia drugs made by Amgen Inc and Johnson & Johnson to reflect concerns they may increase the risk of heart attacks, stroke and death, the companies and U.S. regulators said on Thursday.

  • Shire's Third-Quarter Earnings Top Forecast Thursday, 1 Nov 2007 | 10:46 AM ET

    Britain's Shire beat forecasts with a 32 percent rise in third-quarter underlying earnings on Thursday and said its new hyperactivity drug, Vyvanse, had been well received by doctors and patients.

  • Health Care Stocks to Watch Thursday, 25 Oct 2007 | 10:55 AM ET

    Even as much of the economy contracts, health care continues to grow, and investment opportunities continue to grow with it. What to choose among those investment opportunities? Analyst Michael Magiera of Manning & Napier looks past some of the more volatile pharmaceutical stocks.

  • Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Galapagos Signs Major Arthritis Deal with J&J Wednesday, 24 Oct 2007 | 4:21 AM ET

    Belgian biotechnology company Galapagos said on Wednesday it had signed a deal potentially worth up to one billion euros with Johnson & Johnson unit Janssen Pharmaceutica.

  • Abbott Profit Flat as Charges Take Toll Wednesday, 17 Oct 2007 | 1:35 PM ET

    Abbott Laboratories on Wednesday said third-quarter earnings were little changed due to special charges, but the company reported sharply higher sales of its prescription drugs and medical devices.

  • Stocks End Lower on Bernanke's Warning on Economy Tuesday, 16 Oct 2007 | 4:20 PM ET

    Stocks fell after Fed Chairman Ben Bernanke said the housing slump is likely act as a drag on to U.S. economic growth, sparking investor concerns. "It was just last month Bernanke was saying things were contained, but now he's saying housing troubles can spread," said Brian Hicks, president of Wealth Daily. "This-flip flop in the last month has really spooked the markets."

  • J&J Profit Slips on Costs, Raises Full-Year Target Tuesday, 16 Oct 2007 | 12:49 PM ET

    Health care products maker Johnson & Johnson said Tuesday its third-quarter profit fell about 8 percent because of a charge for cutting jobs, primarily in its stent-making and pharmaceuticals businesses.

Most Popular Video

Friday, 18 Apr 2014 | 11:00 AM ET

Are economic growth expectations too high? CNBC's Jeff Cox explains.

Friday, 18 Apr 2014 | 12:00 PM ET

CNBC's Stephanie Landsman discusses how the luxury rental boom isn't confined to New York City and its boroughs, but that developers are seeing new opportunities in New Jersey.

Thursday, 17 Apr 2014 | 12:00 PM ET

CNBC's Josh Lipton and Allison+Partners Head of Digital Jeremy Rosenberg discuss what Microsoft needs to do to boost Xbox One sales as PS4 sales break the 7 million mark.